Condensed Consolidated Statements of Operations and Comprehensive Loss - USD ($) $ in Thousands		3 Months Ended		9 Months Ended
		Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Revenues:
Products, net		$ 207,774	$ 166,911	$ 607,836	$ 433,676
Type of Revenue [Extensible List]		us-gaap:ProductMember	us-gaap:ProductMember	us-gaap:ProductMember	us-gaap:ProductMember
Collaboration		$ 22,495	$ 22,495	$ 66,750	$ 66,750
Total revenues		230,269	189,406	674,586	500,426
Cost and expenses:
Cost of sales (excluding amortization of in-licensed rights)		39,952	23,444	109,190	65,305
Research and development		216,707	139,115	663,286	573,886
Selling, general and administrative		104,787	61,127	330,943	204,605
Settlement and license charges		0	0	0	10,000
Amortization of in-licensed rights		178	178	535	527
Total cost and expenses		361,624	223,864	1,103,954	854,323
Operating loss		(131,355)	(34,458)	(429,368)	(353,897)
Other (loss) income, net:
(Gain) loss on contingent consideration, net	[1]	6,700	7,200	6,700	7,200
Loss on debt extinguishment		(125,441)	0	(125,441)	0
Other expense, net		(6,322)	(20,649)	(40,548)	(52,362)
Gain from sale of Priority Review Voucher		0	0	0	102,000
Total other (loss) income, net		(125,063)	(13,449)	(159,289)	56,838
Loss before income tax expense (benefit)		(256,418)	(47,907)	(588,657)	(297,059)
Income tax expense (benefit)		1,320	237	5,587	(260)
Net loss		(257,738)	(48,144)	(594,244)	(296,799)
Other comprehensive loss:
Unrealized (losses) gains on investments, net of tax		(720)	(22)	(3,185)	(23)
Total other comprehensive loss		(720)	(22)	(3,185)	(23)
Comprehensive loss		$ (258,458)	$ (48,166)	$ (597,429)	$ (296,822)
Net loss per share - basic and diluted		$ (2.94)	$ (0.60)	$ (6.79)	$ (3.72)
Net loss per share - basic and diluted		$ (2.94)	$ (0.60)	$ (6.79)	$ (3.72)
Weighted average number of shares of common stock used in computing basic and diluted net loss per share		87,628	79,880	87,465	79,695
Weighted average number of shares of common stock used in computing basic and diluted net loss per share		87,628	79,880	87,465	79,695

[1] The gain on contingent consideration, net is related to the fair value adjustment of the regulatory-related contingent payments that are accounted for as derivatives. Please see Note 4, Fair Value Measurements for further details.